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Rebuttal to Drs. Spratt and Zelefsky
Nelson N. Stone1,2,*
1Department of Urology, Mount Sinai School of Medicine, New York, NY
2Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NYSpratt and Zelefsky try to make the case that adjustments, it is not difficult to get sufficiently high doses
intermediate-risk prostate cancer should be managed by
a combination of brachytherapy plus external beam irradia-
tion intensity-modulated radiation therapy (IMRT) rather
than brachytherapy alone (1). Unfortunately, for them, their
arguments fall short of convincing brachytherapists. In
table 1, the authors list a number of studies of biochemical
results following brachytherapy alone (1). Although most
of the results appear on the surface to be suboptimal
compared with combination therapy, no data are shown that
separate the higher dose implants from the lower dose ones.
Thus, by presenting data with mixed dosimetry results, the
reader is left with the incorrect impression that monotherapy
is inferior to combination therapy. In addition, Spratt and Ze-
lefsky further make my case for monotherapy by arguing
that combination therapy increases biologic effective dose
(BED) (which it does). As I discussed in my article (2), high
BEDs can be achieved with implant alone.
The authors would like to argue that combination
therapy is also necessary to increase the dose at the margin
of the gland in case capsular penetration is present. We
have always advocated using higher activity seeds placed
just under the capsule (many choose strands placed just
outside the prostate in intermediate risk group patients).
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because of the irregular shape of the prostate and the vari-
ability of its posterior surface in relation to the anterior
rectal wall, implant alone is far more conformal than
combination therapy. The high dose conformity is one of
the reasons there are fewer rectal complications when
implant alone is used instead of combination therapy.
Spratt and Zelefsky anticipate that the results of RTOG
0232 may substantiate their position. Unfortunately, it is
not sufficient to just compare implant alone with combina-
tion therapy without consideration of delivered BED. If
patients are stratified by BED, I predict there will be no
differences in prostate-specific antigen (PSA) control in this
study. Awell done implant should be the treatment of choice
for intermediate-risk prostate cancer patients.References
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